Purpose: To investigate the feasibility and safety of a new small-aperture device, which is implanted on top of the intraocular lens.
Methods: Regular cataract surgery was performed in both eyes in 7 patients. In the non-dominant eye, a small-aperture device (VisionXtender; Morcher) was additionally implanted into the capsular bag at the end of the surgery. The mask had an inner diameter of 1.4 mm. Feasibility and safety were investigated 3 months and 2 years after surgery.
Results: In all cases, the device was successfully positioned in the capsular bag without any intraoperative complications. No inflammation was observed at the 3-month follow-up visit. All patients achieved binocular uncorrected distance visual acuity of 0 logarithm of the minimum angle of resolution (log-MAR) or better. Additionally, distance-corrected intermediate visual acuity of 0.1 logMAR or better was measured in the non-dominant eye. Two years postoperatively, Nd:YAG capsulotomy was performed in three patients in both eyes.
Conclusions: This clinical feasibility trial demonstrates that the use of the new small-aperture device is both easy and safe. No intraoperative or postoperative complications were reported. All patients attained satisfactory distance, intermediate, and near visual acuity. The device shows significant potential when used in combination with different intraocular lenses (eg, toric). In the future, different opening shapes seem to be possible. .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3928/1081597X-20240723-03 | DOI Listing |
Vision (Basel)
November 2024
Department of Experimental Ophthalmology, Saarland University, 66424 Homburg, Germany.
Purpose: The number of presbyopia-correcting (premium) intraocular lenses (IOLs) is growing steadily as the desire for spectacle independence after cataract surgery increases. The aim of this laboratory study was to evaluate a newly launched hydrophobic, acrylic, polyfocal, refractive intraocular lens with a new optical design and geometry. This polyfocal IOL has three different zones (within the optic) with radially asymmetric design.
View Article and Find Full Text PDFPurpose: To evaluate range of visual acuity, visual quality, and safety of the IC-8 small-aperture (SA) intraocular lens (IOL) (Apthera; Bausch & Lomb, Inc) in patients with cataract.
Methods: This was a prospective, multicenter, open-label, parallel-group, non-randomized, examiner-masked, 12-month clinical study conducted at 21 sites in the United States. Included patients (N = 453) received either the SA IOL (targeted to -0.
Purpose: To assess the visual outcomes in patients with cataract implanted with a small-aperture intraocular lens (IOL) in eyes with aberrated corneas.
Methods: This prospective, non-interventional, single-center clinical study was conducted at Singapore National Eye Centre, Singapore. Twenty-one patients with aberrated corneas had IC-8 IOL (Bausch & Lomb, Inc) implantation.
Purpose: To investigate the feasibility and safety of a new small-aperture device, which is implanted on top of the intraocular lens.
Methods: Regular cataract surgery was performed in both eyes in 7 patients. In the non-dominant eye, a small-aperture device (VisionXtender; Morcher) was additionally implanted into the capsular bag at the end of the surgery.
J Cataract Refract Surg
November 2024
From the Summit Eye Care of Wisconsin, Wauwatosa, Wisconsin (Vukich); Vance Thompson Vision, Sioux Falls, South Dakoda; Sanford USD School of Medicine, Sioux Falls, South Dakota (Thompson); Virginia Eye Consultants, Norfolk, Virginia (Yeu); Cleveland Eye Clinic, Elyria, Ohio (Wiley, Bafna); Baylor College of Medicine, Houston, Texas (Koch); Acufocus, Inc., Irvine, California (Lin, Michna).
Purpose: To evaluate depth of focus (DOF) and visual acuities (VAs) by manifest refractive spherical equivalent (MRSE) and degree of preoperative corneal astigmatism with the IC-8 small aperture intraocular lens (SA IOL) (Apthera).
Setting: 21 investigational sites in the United States.
Design: Prospective, multicenter, open-label, parallel-group, nonrandomized, examiner-masked, 1-year clinical study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!